Abstract Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ERstress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development.
Introduction
Pancreatic beta-cells maintain glucose homeostasis via the regulated secretion of insulin. Although the etiologies of type 1, type 2 and monogenic diabetes are different, they share similarities in the molecular pathways that become dysregulated in beta-cells during disease progression. Among these, endoplasmic reticulum (ER) stress and unfolded protein response (UPR) seem to be critical for the proper function and resilience of the beta-cell, and their role has been studied in different diabetes models (Brozzi and Eizirik, 2016; Cnop et al., 2017; Herbert and Laybutt, 2016) . High quantities of insulin are transcribed, translated and ultimately secreted by beta-cells. This requires the establishment of appropriate mechanisms for proinsulin translation, folding, processing, storage and eventual secretion of mature insulin (Steiner et al., 2009) . To cope with both the constant basal insulin secretion and the dynamic demand in response to elevated circulating glucose, the UPR is highly efficient in beta-cells, and adapts the ER loading and protein folding capacity to the insulin biosynthesis rate (Back and Kaufman, 2012; Vander Mierde et al., 2007) . High levels of insulin biosynthesis generate a chronic sub-threshold ER-stress that suppresses beta-cell proliferation (Szabat et al., 2016) , while induction of mild ER-stress in the context of hyperglycemia has been shown to induce beta-cell proliferation (Sharma et al., 2015) . These findings highlight the important link between insulin expression, UPR levels and beta-cell proliferation.
Permanent neonatal diabetes mellitus (PNDM) is caused by mutations in genes controlling betacell development or functionality, and is usually diagnosed before 6 months of age (Greeley et al., 2011; Murphy et al., 2008) . The development of efficient differentiation protocols has enabled the generation of beta-like cells in vitro from human pluripotent stem cells (hPSC) (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015) . Combined with genome editing technologies, they make possible the establishment of in vitro models for detailed studies of pathogenic mechanisms of PNDM Saarimäki-Vire et al., 2017; Shang et al., 2014; Zhu et al., 2016) . Insulin gene mutations are among the most common causes for PNDM globally (Huopio et al., 2016; Støy et al., 2010) . Dominant negative heterozygous mutations that disrupt cysteine bridges within proinsulin lead to its misfolding, aggregation and accumulation in the ER (Herbach et al., 2007; Liu et al., 2010a; Park et al., 2010; Rajan et al., 2010) . Accordingly, these high molecular weight proinsulin aggregates increase ER-stress and activate the UPR. Sustained UPR activation results in beta-cell dysfunction and the eventual onset of diabetes (Colombo et al., 2008; Liu et al., 2010b) . This phenomenon has been studied extensively in the Akita mouse model of diabetes, which carries a proinsulin cysteine disruption mutation (C96Y) that leads to mutant proinsulin accumulation in the ER, enlarged ER, reduction of secretory granules and mitochondrial swelling (Izumi et al., 2003; Kayo and Koizumi, 1998; Wang et al., 1999; Yoshioka et al., 1997; Zuber et al., 2004) . Similar findings have been reported from the Munich mouse model carrying Ins2 C95S mutation (Herbach et al., 2007) . Although further studies suggested that unresolved UPR resulted in beta-cell apoptosis via Chop (Ddit3) induction (Oyadomari et al., 2002) , significant differences in the number of apoptotic beta-cells were not observed in either model (Herbach et al., 2007) .
To study the role of proinsulin cysteine disrupting mutations in human beta-cells, we derived human induced pluripotent cell lines (iPSC) from Finnish people carrying C96R (the same cysteine as eLife digest Insulin is a hormone that is crucial for maintaining normal blood sugar levels and is produced by so called beta cells in the pancreas. If the beta cells in the body stop making insulin, blood sugar levels start to rise, which can lead to diabetes. A form of diabetes known as neonatal diabetes, where the body stops making insulin, usually appears during the first six months of life.
Infants affected by this early onset of diabetes often have mutations in one copy of the gene that encodes insulin. This means that they can still produce half of the amount of insulin, but it is not enough to keep blood sugar stable. Instead, insulin production stops completely after a few months. Scientists believe that this is because the mutant insulin has a toxic effect on beta cells.
Mutations in the insulin gene can affect the structure of insulin. As a result, insulin accumulates inside the beta cells, which stresses them and eventually makes them fail. The mechanisms behind this process are still unclear. Now, Balboa et al. used stem cells (which can turn into other cell types) taken from patients with this rare type of insulin mutation to find out more.
They corrected the mutant insulin gene in these stem cells with a technique called CRISPR and then induced the mutant and corrected stem cells to turn into beta cells. The results showed that the mutant beta cells slowed down their rate of cell division but did not die more frequently. When the cells were implanted into mice their growth and development changed. The mutant cells were more stressed and smaller than the cells with the repaired genes. They also had fewer signalling molecules that help cells grow. As a consequence, the cells were struggling to grow and mature.
Although this type of diabetes is rare, beta cells come under stress in other forms of the disease. In a separate study, Riahi et al. found that boosting molecular signals for cell growth could protect beta cells in mice with mutant insulin. If this could also work in humans, it may lead to new ways to prevent diabetes.
the Akita C96Y mutation) and C109Y insulin mutations (Huopio et al., 2016) and differentiated them in vitro to beta-like cells. To circumvent the challenges associated with variable iPSC differentiation efficiency, we employed isogenic correction of the cell lines using CRISPR-SpCas9 Hsu et al., 2014) . Single-cell RNA sequencing of the in vitro differentiated cells showed increased expression of ER stress-associated transcripts in the INS mutant cells, in concert with reduced proliferation. To further study the properties of these beta-like cells in vivo, we performed transplantation experiments into immunocompromised mice. Transplanted INS mutant betalike cells exhibited lower insulin secretion and increased levels of ER-stress markers, together with reduced mTORC1 signaling and beta-cell size, without any apparent increase in apoptosis. Our findings suggest that PNDM-associated insulin mutations lead to inadequate development of a functional beta-cell mass.
Results

Derivation of induced pluripotent stem cells from people with neonatal diabetes carrying mutations in the insulin gene
We studied two Finnish families with hereditary neonatal diabetes due to heterozygous insulin gene mutations ( Figure 1-figure supplement 1A ). Both missense mutations affect cysteine residues, resulting in the disruption of the proinsulin inter-chain disulphide bonds A7-B7 (mutation C96R) and A20-B19 (mutation C109Y) ( Figure 1B ) which are essential for the proper folding and biological activity of the insulin molecule (Chang et al., 2003) .
Affected individuals of these families become hyperglycemic 3-4 months after birth. Prior knowledge about the insulin gene mutations in the families enabled the neonatal genetic diagnosis in newborn siblings. Two affected newborns were monitored for the development of the disease. They were born at normal gestational age, presenting normal birth weight and fasting plasma c-peptide levels ( Figure 1-figure supplement 1A) . Continuous subcutaneous glucose monitoring demonstrated the gradual deterioration of glycemia during the first months of life ( Figure 1A , Figure 1 figure supplement 1B).
We derived induced pluripotent stem cells (iPSC) from the affected parents using retroviral and Sendai virus-mediated delivery of reprogramming factors OCT4, SOX2, KLF4 and MYC to dermal fibroblasts obtained from skin biopsies (Figure 1-figure supplement 2A ). Established iPSC were cultured for at least ten passages and then characterized. They expressed hallmark pluripotency markers, presented normal karyotypes and were able to spontaneously differentiate to the three germ layers in embryoid bodies (Figure 1-figure supplement 2C-E) . Sequencing of the insulin locus confirmed the presence in heterozygosis of the T to C change causing C96R mutation (iPSC line HEL71.4) ( Figure 1C ) and G to A change causing C109Y mutation (iPSC line HEL107.2) (Figure 1-figure supplement 2B ).
CRISPR/Cas9-mediated correction of INS C96R mutation in patient derived iPSCs
Differentiation protocols devised to obtain beta-cells from human pluripotent stem cells (PSC) are not equally efficient across cell lines (Nostro et al., 2015; Sui et al., 2018) . For disease modeling purposes, this variation in the differentiation from iPSC with different genetic backgrounds might obscure the phenotype caused by the mutation under study.
Thus, we generated mutation-free isogenic iPSC lines from the patient-derived HEL71.4 line by correcting the C96R mutation using CRISPR/SpCas9 genome editing ( Figure 1C ). Different guide RNAs were designed to target as close as possible to the C96R mutated codon in the insulin locus and tested in HEK293 cells. A guide RNA (Ins8) cutting 9 base pairs away from the point mutation showed high cutting efficiency by T7 assay (Figure 1-figure supplement 2F -G). We tested a mutation correction strategy based on homology directed repair (HDR) stimulated by the Ins8 guide RNA cutting activity using a single stranded DNA oligo (ssODN) of 70 bases as a donor template ( Figure 1C , Figure 1-figure supplement 2F ). The correction donor ssODN contained the wildtype nucleotide in the mutation position (wild-type Cys TGT instead of mutant Arg CGT) and a synonymous point mutation in the next codon that created a restriction site for BsrGI (Thr ACC instead of Thr ACA) enabling rapid screening of the recombinant clones. The recombination of the ssODN was efficient in HEK293 cells (Figure 1-figure supplement 2F-G) . Next, we delivered the SpCas9-T2A-EGFP expressing plasmid, Ins8 gRNA and ssODN to patient iPSC HEL71.4 and sorted them based on EGFP+ expression. Sorted cells were pooled together, expanded and single-cell sorted to 96-well plates. We recovered 27 iPSC colonies out of 384 sorted single cells (Cloning efficiency = 7.03%). We screened the clones by PCR followed by BsrGI restriction and found 17 recombinant clones (17/22 = 77% recombinant) (Figure 1-figure supplement 2H ). Recombinant clones were further examined by Sanger sequencing ( Figure 1C ). Clones F2, F10, G6 and A2 presented correction of the mutation with no chromosomal abnormalities ( Figure 1-figure supplement 2I ). No mutations in putative off-targets were found in any clone (Supplementary file 1 - Table 1) .
For the differentiation and transplantation experiments in this study we have used the C96R mutant iPSC line HEL71.4 (INS C96R), its corrected clones (INS corrected) and the C109Y mutant iPSC line HEL107.2 (INS C109Y).
Differentiation of INS mutant and corrected iPSC lines to beta-like cells
We utilized a previously described protocol to differentiate beta-cells from iPSC (Saarimäki-Vire et al., 2017) (Figure 1-figure supplement 3A) . All INS mutant and INS corrected iPSC lines differentiated efficiently into definitive endoderm on day 3 ( Figure 1D ) and progressed to the pancreatic progenitor stage on day 12, presenting abundant PDX1+, NKX6.1+ and SOX9+ cells, with few NEUROG3+ and endocrine CHGA+ cells (Figure 1-figure supplement 3B) .
At the pancreatic progenitor stage (Stage 4, 12 days of differentiation) cells were dissociated and plated in suspension in a rotational platform, forming 3D islet-like aggregates that differentiated further to the endocrine lineage. After 30 days of differentiation (final Stage 7, S7), we characterized the islet-like aggregates by cytometry. Differentiations from INS mutant and INS corrected iPSC yielded S7 aggregates that were composed of cells expressing PDX1 (an average across all iPSC lines of 73 ± 12% SD PDX1+ cells, n = 10) and NKX6.1 (an average across all iPSC lines of 37 ± 15% SD, NKX6.1+, n = 23) ( Figure 1E ) (Figure 1-figure supplement 3B-C) . On average across all iPSC lines, 41% (±14% SD, n = 25) of the S7 cells were INS+, with 18% (±6% SD, n = 23) of the cells expressing both INS and NKX6.1, a sign of bona fide beta-cells (Nostro et al., 2015) (Results pooled by genotype presented in Figure 1E -F, results of individual iPSC lines presented in Figure 1-figure supplement 3C ). The number of INS+ cells at S7 was significantly different between INS mutant (31 ± 10% SD; n = 9) and corrected cells (49 ± 13% SD; n = 16) ( Figure 1E , Figure 1 -figure supplement 3C).
Subsequent analyses focused particularly on the INS+ cells at the Stage 7 of in vitro differentiation or 1, 3 or 6 months after transplantation under the kidney capsule of immunodeficient NSG mice.
Single-cell RNA sequencing revealed increased ER-stress and impaired proliferation of INS mutant beta-like cells Bulk RNA isolation has been traditionally used to study gene expression in cell samples using RTqPCR or RNA-seq analysis. Using these methods, the identity of the cell source of a given RNA transcript is lost. Moreover, cell sample heterogeneity might introduce a lot of variation when studying a particular cell-specific transcript. Of note, independent iPSC to beta-like cell differentiation experiments vary in the yield of INS+ cells (Figure 1-figure supplement 3C ). The use of bulk RNA analysis to study the effects of the INS mutation in the beta-like cells might therefore obscure subtle transcriptional differences between the INS mutant and corrected cells. To overcome this problem we performed InDrop droplet-based single-cell RNA sequencing (scRNAseq) on differentiated isletlike cells (Baron et al., 2016; Klein et al., 2015) .
A Table 2 ) (Segerstolpe et al., 2016) . The highest levels of INS expression were observed in the beta-like cluster ( Figure 2B-C) . A resampling procedure confirmed the robustness of the clustering results (Figure 2-figure supplement 4C-D) .
To confirm and to strengthen the identity of the sequenced cells, we compared our scRNA-seq data with a previous published human adult islet scRNAseq dataset generated with the InDrop single-cell platform (Baron et al., 2016) . Mapping of the individual cells to the Baron et al. (2016) dataset confirmed the identity of the beta-cells and was utilized to further refine the clustering of the beta-like and progenitor clusters, filtering out cells that mapped to the alpha cell cluster ( Tables 3 and 4) . Mutant beta-like cells presented significant upregulation of chaperone genes HSPA5, HSPA8 and HSP90B1, disulfide isomerase PDIA6, ubiquitin gene UBB and components of the ER associated degradation (ERAD) pathway HM13, HERPUD1, SEC61B and SDF2L1. SDF2L1 expression is induced upon overexpression of the Akita mouse model C96Y mutant INS and it has been shown to interact with misfolded proinsulin and mediate its degradation (Figure 2-figure supplement 1C ) (Hartley et al., 2010; Tiwari et al., 2013) . These transcriptional changes indicate that the INS C96R mutation causes ER-stress and the subsequent activation of the UPR. Expression of the CDKN1C gene was also increased. The gene product, p57/Kip2, is an important inhibitor of human beta-cell proliferation (Avrahami et al., 2014) , suggesting reduced proliferation of the INS C96R cells. Interestingly, the INS gene was upregulated in INS C96R cells, together with other insulin secretion related genes (CPE, SCGN, DLK1), a phenomenon previously described in young Akita mice (Oyadomari et al., 2002) ( Gene set enrichment analysis (GSEA) was performed on the differentially expressed genes in the beta-cell cluster. Ribosomal translation, insulin synthesis and processing, diabetes pathways and ATF6-controlled UPR chaperones gene sets were overrepresented among the genes upregulated in INS C96R cells. On the contrary, the genes downregulated in INS C96R were enriched in gene sets related to EGF signaling and respiratory electron transport, processes important for beta-cell development and function. In the progenitor cluster, GSEA showed overrepresentation of GLIS3 targets and peptide chain elongation in the INS C96R upregulated genes, while SRC, TGF-beta and EGF Mitochondrial oxidative phosphorylation, regulation of macromolecule metabolic processes and mitotic cell cycle Gene Onthology (GO) biological processes were enriched among the genes downregulated in the beta-like cluster INS C96R cells. Intracellular transport, protein targeting to ER and protein folding GO terms were enriched among the upregulated genes. Similar GO terms were enriched in the down and upregulated genes of the progenitor cluster (Supplementary file 1 - Table 6 , Figure 2 -source data 2).
We hypothesized that the endocrine progenitor population identified by the clustering is in the process of differentiating towards endocrine (mainly alpha-like and beta-like) cells. To investigate the hierarchy of differentiation events, we performed pseudotime analysis to infer the possible trajectories of these populations (Qiu et al., 2017) . The analysis algorithm imposed a branched trajectory, in which the progenitor cluster cells were split in two distinct progenitor branches that merge to give rise to the beta-like cell branch ( Figure 2E , Figure 2-figure supplement 2A) . The differentially expressed genes between these two progenitor populations suggest that Progenitor one may represent early endocrine progenitors, expressing higher levels of HES1, PAX6, PROX1 and other genes related to cytoskeleton regulation, cell adhesion, migration and TGF-beta signaling modulation ( Figure 2E Table 7 ). The Progenitor two population presents higher levels of NEUROD1, CHGA and FEV, suggesting a more advanced, already granulated, late endocrine progenitor identity.
Analysis of differentially regulated genes along the pseudotime trajectory showed that the expression dynamics of INS and other proliferation (ID2, CDKN1C) and UPR-related genes (HSPA5, PDIA6, SDF2L1) were significantly different between INS C96R and INS corrected cells ( Figure 2F , Figure 2 -figure supplement 2D, Supplementary file 1 - Table 8 ). This illustrates the significantly higher upregulation of ER-stress markers, INS and CDKN1C cell cycle inhibitor earlier in the differentiation trajectory of INS C96R progenitors to beta-like cells, indicating the immediate negative effect of misfolded proinsulin in the recently committed beta-like cells upon INS expression.
Increased ER-stress and reduced proliferation of INS mutant beta-like cells in vitro
To determine the expression of different ER-stress markers at the protein level, we performed immunohistochemistry of stem cell-derived Stage 7 beta-like cells cultured in vitro. Immunoreactivity for qRT-PCR analysis confirmed the significantly increased expression of ER-stress markers BIP, sXBP1, MANF and GRP170, in line with the findings of immunostainings and scRNAseq results ( Figure 3C ). Other ER-stress associated genes, including CHOP (DDIT3), which has been reported to be upregulated in Akita mice (Oyadomari et al., 2002) , were not differentially expressed at the mRNA level between INS C96R and corrected cells ( Figure 3C ). However, the expression of CHOP and ATF transcription factors might be also regulated post-transcriptionally (Cnop et al., 2017) . To determine if the INS C96R beta-like cells under ER-stress are more sensitive to apoptosis, TUNEL assays were performed on S7 aggregates. The ratio of TUNEL+/INS+ cells was similar in INS C96R and INS corrected cells in the basal conditions (about 1%) ( Figure 3D ). Induction of additional ERstress by treatment with brefeldin A (BFA), thapsigargin (TGA) or tunicamycin (TM) resulted in increased apoptosis for both genotypes. BFA, but not the other stressors, induced a significantly higher level of apoptosis in the INS C96R cells compared to mutation corrected cells ( Figure 3D ). Thus, INS C96R beta-like cells present higher sensitivity to apoptotic cell death induced by further increasing ER-stress with BFA treatment.
The insulin secretory responses of S7 beta-like cells were assessed by sequential static incubations in the presence of 1 mM forskolin to increase cAMP levels. While the response to high glucose alone was minimal (1.15-and 1.05-fold for INS C96R and corrected cells, respectively), tolbutamide and KCl triggered robust insulin secretion (2.5-and 3.2-fold for both INS C96R and corrected cells). The fractional release of insulin (as % of content) was not significantly different between INS C96R and corrected cells ( Figure 3E ). However, the insulin content of the INS C96R S7 islet-like aggregates was significantly reduced (5.2-fold lower than in corrected) ( Figure 3F 
INS mutant beta-like cells presented reduced insulin secretion after in vivo transplantation
Islet-like cell clusters from INS C96R, INS C109Y and corrected cell lines were transplanted under the kidney capsule of NSG mice to study the effect of the insulin mutation on beta-like cells in vivo ( Figure 4A ). Graft functionality was tracked from 1 to 6 months after transplantation by measuring circulating human C-peptide in plasma samples from randomly fed mice. Mice carrying INS C96R and INS C109Y grafts presented significantly lower levels of human C-peptide than mice carrying INS corrected grafts ( Figure 4B ). The levels of C-peptide increased from the 2 month time point onwards for the INS corrected grafts (p < 0.0001, One-way ANOVA), while no change was observed in the INS C96R and INS C109Y grafts ( Figure 4B ). The increase in circulating human C-peptide in INS corrected grafts can be attributed to further expansion and maturation of the transplanted betalike cells. Additionally, differentiation of co-transplanted pancreatic progenitors to the beta-cell lineage is likely to contribute as well.
Intraperitoneal glucose tolerance test performed at 3 or 6 months after grafting showed that INS corrected grafts presented higher insulin secretion levels than INS C96R and INS C109Y grafts, both upon fasting and after glucose injection ( Figure 4C-D) . Mice transplanted with INS C96R grafts presented a trend towards elevated ratio of circulating proinsulin to circulating C-peptide ( Figure 4E ), a phenomenon that has been previously described in humans with mutant insulin diabetes (Liu et al., 2010b; Liu et al., 2015; Rajan et al., 2010) .
Elevated ER-stress levels in INS mutant beta-like cells after transplantation without increased apoptosis (Sharma et al., 2015) . We examined the relationship between the proliferation marker PCNA and the ER-stress marker BIP, but we did not find a consistent correlation (Figure 5-figure supplement 2A). We performed a similar analysis for proliferation marker KI67 and the intensity of INS and PROINS immunostaining, since decreased levels of INS expression have been associated with increased beta-cell proliferation (Szabat et al., 2016; Xin et al., 2018) . KI67+ cells presented reduced INS immunostaining intensity across genotypes and time points, suggesting a possible correlation between reduced INS expression and increased proliferation (Figure 5-figure supplement 2B-C).
Similar to proinsulin, MANF immunoreactivity occupied most of the cytoplasm in INS C96R cells, indicating accumulation in a distended ER ( Figure 5D ) (Lindahl et al., 2014) . To detect if MANF was released from the cells under ER-stress, we measured it in vitro and in transplanted animals. Overnight MANF secretion tended to be elevated in the INS C96R in vitro cells, but this difference was not significant (Figure 3-figure supplement 1D ). Circulating human MANF levels were below detection limits in the blood of transplanted animals.
Apoptotic INS+ cells assayed by TUNEL or CASP3 staining were very rare at all time points (<0.5% at 3 months, not significantly different) (Figure 3-figure supplement 1F) , suggesting that aggravated ER-stress does not lead to increased apoptosis of the INS C96R or INS C109Y cells in vivo.
INS mutant grafts presented altered endocrine cell proportions and PDX1 expression
The proportion of INS+ cells was significantly reduced in INS C96R grafts at 3 months. This finding was further confirmed by immunohistochemistry for C-peptide (CPEP) ( Figure 6A-B) . On the contrary, the glucagon (GCG) positive cell compartment was increased ( Figure 6A-B) . We examined other endocrine hormones and found that there were no significant differences in the ratios of somatostatin (SST) positive or pancreatic polypeptide (PP) positive cells. However, the percentage Figure 6C) .
The proportion of cells co-expressing PDX1 and C-peptide was significantly reduced in 3-monthold grafted INS C96R beta-cells ( Figure 6A,D) . Proliferation of INS C96R beta-like cells was significantly impaired at S7 in vitro ( Figures 3B and 6E-F) . Following transplantation, this difference gradually disappeared as the proliferation of INS corrected cells decreased ( Figure 6D-F) . This may recapitulate human postnatal beta-cell development, with a postnatal peak of proliferation that declines rapidly during the first two years of life (Gregg et al., 2012; Meier et al., 2008) . mTORC1 signaling was dysregulated in INS+ mutant cells mTORC1 signaling is required for the proper postnatal growth and maturation of beta-cells (Ni et al., 2017; Sinagoga et al., 2017) . Single-cell RNA-seq revealed downregulation of genes involved in proliferation, oxidative phosphorylation and mTORC1 regulation (LAMTOR5) in INS C96R beta-like cells. These processes are in part regulated by mTORC1 signaling, suggesting that it could be dysregulated in INS C96R cells. We found that immunoreactivity for phosphorylated S6, a central downstream signaling target of mTORC1, was significantly reduced in INS+ 3 month-old INS C96R grafts ( Figure 7A-C) . Consistent with reduced mTORC1 signaling, INS+ cell size was also significantly reduced in the INS C96R grafts ( Figure 7B-C) .
Based on the findings of the sc-RNAseq analysis on the in vitro beta-like cells, we examined the expression of mitochondria respiratory chain subunits in 3 month old grafts ( Figures 2D and  7D) . Immunostaining for MT-CO1, MT-CO2 and TOM20 revealed an altered, more condensed and globular mitochondrial morphology as well as decreased immunofluorescence intensity in INS + mutant cells ( Figure 7D-E) . Interestingly, INS staining intensity was also decreased at this point, suggesting a reduced INS protein content in the grafted beta-like cells ( Figure 7E ).
Discussion
We interrogated the impact of insulin gene mutations on beta-cell development by generating a model based on genome edited patient-derived iPSC Saarimäki-Vire et al., 2017; Shang et al., 2014; Zhu et al., 2016) . iPSC provide a novel possibility to study mechanisms of beta-cell dysfunction using patient cells. However, this approach is still being developed and presents important caveats that need to be taken into account. The in vitro-differentiated beta-like cells are functionally immature, which limits their usefulness particularly to model metabolically controlled insulin secretion. Also, the variability of differentiation efficiency across cell lines has been a confounding factor. Genome editing technologies have partially solved this problem by enabling the generation of isogenic cell lines. We combined this approach with single-cell transcriptomics, enabling the detection of ER-stress early during the development of beta-cells as the consequence of accumulation of misfolded mutant proinsulin. Impaired beta-cell proliferation was the most striking phenotype of the mutated cells. Following transplantation, the INS mutant cells presented increased proinsulin accumulation and further increased signs of ER-stress, associated with reduced PDX1 expression and reduced beta-cell size, as well as mitochondrial alterations. Many of these features are attributable to the observed decreased mTORC1 signaling.
Since populations of endocrine cells generated with the available differentiation protocols (Pagliuca et al., 2014; Rezania et al., 2014; Russ et al., 2015) are heterogeneous, single-cell RNAseq methods provide a robust approach to identify and characterize specifically bona-fide beta-like cells . Single-cell RNA-seq has been recently used to study both mouse and human islets in different stages of development and disease (Baron et al., 2016; Segerstolpe et al., 2016; Xin et al., 2018; Zeng et al., 2017) . These datasets can now be compared with in vitro hPSCderived beta-cells to verify the identity of the endocrine cells, as we present here (Figure 2-figure  supplement 1B) . Moreover, single-cell transcriptomic data enables the use of pseudotime analysis to infer differentiation trajectories. This is particularly useful to elucidate hierarchical and temporal relationships between cell types in developing tissues and in vitro differentiation experiments (Qiu et al., 2017) . Using this approach, we identified a differentiation trajectory with two distinct endocrine progenitor stages, an earlier progenitor population marked by PROX1, HES1 and ID2, and a more differentiated progenitor population marked by CHGA, NKX2.2, FEV, NEUROD1 and MNX1. These two types of progenitors likely represent sequential stages in the differentiation to beta-like cells, which are depicted as independent populations due to the branching trajectory imposed by the analysis algorithm. Interestingly, two putative endocrine progenitor populations have been also observed in a recent study where the stages of hPSC differentiation towards beta-cells were examined by singlecell qRT-PCR (Petersen et al., 2017) . Further research will be required to determine if these different endocrine progenitor populations have in vivo counterparts in human embryonic pancreas or rather represent an in vitro artifact.
Diabetes caused by misfolded proinsulin has been studied extensively in the Akita mouse model carrying the INS C96Y mutation (Izumi et al., 2003; Oyadomari et al., 2002; Wang et al., 1999) and in the Munich mouse model carrying the INS C95S mutation (Herbach et al., 2007) . These mice become progressively diabetic 4 to 8 weeks after birth, presenting a reduced beta-cell mass which has commonly been attributed to increased apoptosis (Oyadomari et al., 2002) . However, significantly increased beta-cell apoptosis was not detected in some of the studies published with these models (Herbach et al., 2007; Izumi et al., 2003) . A closer examination of the Akita mouse postnatal development has revealed reduced proliferation and impaired function of neonatal beta-cells, in the absence of increased apoptosis (Riahi et al, accompanying paper). These findings are well in line with the results of our study, since we could not detect increased apoptosis in the INS mutant cells at any point, despite the elevated ER-stress manifested by the high expression of BIP, MANF and GRP170. A potential caveat of our model is that grafted mice employed in this study were normoglycemic. It remains to be elucidated if additional ER-stress imposed by increased insulin demand in a diabetic environment would eventually lead to increased apoptosis of human INS mutant beta-cells in vivo.
Disruption of mTORC1 signaling is a crucial link between aggravated ER-stress and defective beta-cell expansion in the neonatal period (Sinagoga et al., 2017) . Inhibition of mTORC1 signaling in Raptor KO mouse beta-cells leads to impaired postnatal beta-cell growth, function and mitochondrial function (Ni et al., 2017) . Restoration of the mTORC1 signaling was sufficient to rescue the beta-cell proliferation defect in Akita mice (Riahi et al., accompanying paper). All these results are in agreement with our findings, where the INS mutant beta-cells show reduced mTORC1 signaling (decreased LAMTOR5 expression, reduced S6 phosphorylation) and would explain their diminished cell size, altered mitochondria and INS protein content.
ER-stress and mitochondrial function are closely associated in the etiology of diverse diseases. For example, ER-stress signaling pathway component PERK has been shown to regulate mitochondrial morphology (Lebeau et al., 2018) . In the context of ER-stress induced by misfolded proinsulin, Akita mouse beta-cells present increased mitochondrial dysfunction, with mitochondrial fragmentation and reduced respiration (Mitchell et al., 2013) . We observed similar mitochondrial defects by scRNA-seq and immunostaining INS mutant beta-cells in vitro and in vivo.
In both rodents and humans, beta-cell proliferation peaks in the neonatal period (Finegood et al., 1995; Gregg et al., 2012; Zeng et al., 2017) . A recent scRNA-seq study shows that neonatal proliferative mouse beta-cells are characterized by high mitochondrial membrane potential, expression of immediate early genes Fos, Egr1, Jun and Srf and increased PI3K-mTOR signaling . Similar scRNA-seq analysis of human adult beta-cells has shown that beta-cells with high expression of UPR and lower expression of insulin are more prone to proliferate (Xin et al., 2018) . These cells are more metabolically active, as reflected by their higher expression of glycolytic pathway, tricarboxylic acid cycle and electron transport chain genes.
Interestingly, our scRNA-seq analysis shows downregulation of similar gene sets, including mitochondrial respiratory chain subunits (MT-CO1, MT-CO2), immediate early genes (FOS, EGR1 and IER) and LAMTOR5 in INS C96R beta-like cells ( Figure 2D, Figure 2-figure supplement 1C) . Furthermore, basic helix-loop-helix (bHLH) transcription factors ID1, ID2 and ID3 were downregulated in the INS C96R cells. These genes, regulated by BMP signaling, are important for the proliferation and differentiation of beta-cells (Hua and Sarvetnick, 2007) . Taken together, our single-cell transcriptomic results provided a basis for the reduced proliferation and altered mitochondria of INS mutant beta-like cells, that was later confirmed in vitro and in vivo.
MANF is an ER-stress induced prosurvival factor whose role in reducing UPR activation is critical for mouse beta-cell development and postnatal beta-cell mass expansion and maintenance (Danilova et al., 2018; Lindahl et al., 2014) . Manf KO mice presented reduced beta-cell mass and beta-cell proliferation at birth, without increased apoptosis, highlighting the importance of maintaining a physiological level of ER-stress for perinatal beta-cell proliferation. Thus, it is possible that the lack of ER-stress-induced beta-cell apoptosis is in part explained by the high MANF expression triggered by the misfolded proinsulin. Interestingly, we detected increased apoptosis in the INS C96R beta-like cells after inducing additional ER-stress with brefeldin A, but not with other stressors ( Figure 3D) . This difference could be the result of the particular brefeldin A mechanism of action, the inhibition of protein transport from ER to Golgi apparatus, which results in additional ER overloading (Helms and Rothman, 1992) .
Impaired beta-cell proliferation resulted in skewed endocrine cell proportions with less insulinpositive and more glucagon-and ghrelin-positive cells. Ghrelin-positive cells represent a transient fetal endocrine cell population (Arnes et al., 2012) , rare in adult human islets (Segerstolpe et al., 2016) . Mouse adult beta-cells have been shown to lose their identity and misexpress ghrelin upon Pax6 deletion, together with an expansion of the islet alpha-cell population (Swisa et al., 2017) . Interestingly, we detected reduced expression of PAX6 in vitro and lower PDX1 expression in vivo in the INS mutant cells. Therefore, a small percentage of the cells could have differentiated into alternative cell identities although our results indicate that impaired proliferation and growth is likely to be the main cause for the demise of the INS mutant cells. A potential limitation in the analysis of grafted cells is the extensive ischemia induced cell death upon transplantation (Faleo et al., 2017) , which could skew cell type proportions and increase graft to graft variability.
Overall Our study extends the observations from the diabetic Akita model into human diabetes and further emphasizes the role of ER-stress in controlling beta-cell proliferation. These findings may be of relevance for the risk of developing type two diabetes later in life, since the functional beta-cell reserve is established in the perinatal period (Gregg et al., 2012; Meier et al., 2008) . 
Materials and methods
Key resources table
hiPSC derivation
Dermal fibroblasts obtained from a skin biopsy were reprogrammed using retroviral delivery of the OCT4, SOX2, MYC and KLF4 transcription factors, as described elsewhere (Toivonen et al., 2013) . hiPS cells were cultured on Matrigel (BD Biosciences)-coated plates with E8 medium (Life Technologies, A1517001) and passaged using 5 mM EDTA (Life Technologies, 15575-038) as a dissociation agent. For pluripotency characterization, cells were spontaneously differentiated using embryoidbody assay . Karyotype analyses based on chromosomal G-banding were performed at Yhtyneet Medix Laboratories, Helsinki, Finland. All hiPSC lines were authenticated using Sanger sequencing for the insulin gene mutations and were negative for mycoplasma contamination test.
Genome editing
Guide RNAs (gRNAs) targeting the insulin locus were designed using web-based tool http://crispr. mit.edu (Hsu et al., 2013) , selecting for guide RNAs with high quality scores to avoid possible offtargets. Transcriptional units for gRNA expression were prepared by PCR and transfected to HEK293 cells together with WT SpCas9 expressing plasmid CAG-Cas9-T2A-EGFPires-puro (Addgene plasmid # 78311). Cutting efficiency was determined using T7 endonuclease I (New England Biolabs) assay (PCR primers: hIns_1229_Fw: GGGTGACCCTCCCTCTAACC, 3'InsRv: TCAGCGGCCGCTCCACAGGGACTCCATCAGA). gRNA Ins8 (CTGGTAGAGGGAGCAGATGC-TGG) was found to cut with high efficiency 9 bp away from the INS C96R mutation. A correction strategy was devised, based on the recombination with a 70 bases single stranded DNA oligo (ssODN), complementary to the Ins8 gRNA. This ssODN corrects the C96R mutation and introduces a synonymous coding nucleotide change, disrupting the protospace adjacent motif (PAM) and creating a novel BsrGI restriction site that facilitates the screening of recombinant clones (Figure 1-figure supplement 2) (ssODN_Ins8_BsrGI:GCAGAAGCGTGGCATTGTGGAACAATGCTGTACAAGCA TCTGCTCCCTCTACCAGCTCGAGAACTACTGC). For correction of the mutation in the patientderived iPSC, two million HEL71.4 cells were electroporated with 6 mg of CAG-Cas9-T2A-EGFP-irespuro endotoxin-free plasmid, 500 ng of gRNA-PCR Ins8 product and 6 mg ssODN (Neon Transfection System, 1100 V, 20 ms, two pulses, ThermoFisher). Cells were immediately plated onto Matrigel-coated plates containing E8-medium with 5 mM ROCK inhibitor (Y-27632 2HCl, Selleckchem).
Cells positive for GFP fluorescence were pool-sorted 48 hr later and expanded. Single-cell sorting was performed as previously described (Saarimäki-Vire et al., 2017) . Plasmids and detailed protocols have been deposited on Addgene (http://www.addgene.org/78311/).
Differentiation experiments
For differentiation of iPSC to beta-cells a modification of previously published protocols was used (Pagliuca et al., 2014; Rezania et al., 2014) , as described previously (Saarimäki-Vire et al., 2017) (Figure 1-figure supplement 3A) . Cells were dissociated with 5 mM EDTA treatment for 10 min and seeded at 1.5-2 million cells/3.5 cm well on Matrigel-coated plates with E8 medium containing 5 mM ROCK inhibitor (Y-27632 2HCl, Selleckchem). Differentiation was started 24 hr later and proceeded through seven stages differentiation protocol (Stages 1 to 4 in adherent culture and stages 5 to 7 in suspension culture):
. Definitive endoderm induction (3 days): cells were washed 1xPBS (without Ca2+/Mg2+) and 2 mL medium/3.5 cm well of differentiation media was applied: MCDB131 (10372-019, Life Technologies)+2 mM Glutmax (35050038, Life Technologies)+1.5 g/L NaHCO3 (SigmaAldrich) + 0.5% BSA fraction V Fatty acid free (Sigma-Aldrich) + 10 mM final glucose (SigmaAldrich) + 100 ng/ml ActA + 3 mM CHIR. CHIR concentration was reduced to 0.3 mM and 0 mM on day 1 and day two respectively.
. Stage 2 posterior foregut induction (for 3 days, medium changed every day): MCDB131 + 2 mM Glutmax + 1.5 g/L NaHCO3 + 0.5% BSA fV + 10 mM final glucose + 0.25 mM Ascorbic acid (A4544, Sigma-Aldrich)+50 ng/mL FGF7 (Z03047, Genscript)
. Stage 3 pancreatic endoderm induction (for 2 days, medium changed every day): MCDB131 + 2 mM Glutmax + 2.5 g/L NaHCO3 + 2% BSA fV + 10 mM final glucose + 0.25 mM Ascorbic acid + 50 ng/mL FGF7 + 0.25 mM SANT1 (S4572, Sigma-Aldrich)+1 mM RA + 100 nM LDN + 1:200 ITS-X (51500-056, Life Technologies)+200 nM TPB (sc-204424, Santa Cruz).
. Stage 4 pancreatic progenitor induction (3 days, medium changed every day): MCDB131 + 2 mM Glutmax + 2.5 g/L NaHCO3 + 2% BSA fV + 10 mM final glucose + 0.25 mM Ascorbic acid + 2 ng/mL FGF7 + 0.25 mM SANT1 + 0.1 mM RA + 200 nM LDN + 1:200 ITS-X + 100 ng/ mL EGF (AF-100-15, Peprotech)+10 mM Nicotinamide (N0636, Sigma-Aldrich).
. Stage 5 endocrine induction: Cells were washed 2x with EDTA, treated with TrypLE for 10 min at 37˚C, 1 mL/3.5 cm well. Cells were dissociated by pipetting, and spin down for 3 min at 200 rcf. Cells were resuspended in S5 medium with ROCK inhibitor at 10 mM, at a density of one million cells/mL, in a volume of 5 mL, in ultra-low attachment 6-well plates (3471, Corning) and placed in a rotating platform (InforsHT, Celltron) at 95 rpm in the incubator. After 24 hr, cells formed round aggregates and medium was changed to S5 without ROCK inhibitor: S5 medium (for 4 days, changed every day): MCDB131 + 2 mM Glutmax + 1.5 g/L NaHCO3 + 2% BSA fV + 20 mM final Glucose + 1:200 ITS-X + 10 ug/mL Heparin (H3149, Sigma-Aldrich)+0.25 mM SANT1 + 0.05 mM RA + 100 nM LDN + 10 mM ALK5inhII (S7233, Selleckchem)+1 mM GC1 (4554, Tocris)+10 mM Zinc Sulfate (Z0251, Sigma-Aldrich)+20 ng/mL Betacellulin (100-50, Peprotech)+100 nM GSiXX (565789, Millipore).
. Stage 6 media (14 days, change every second day): MCDB131 + 2 mM Glutmax + 1.5 g/L NaHCO3 + 2% BSA fV + 20 mM final glucose + 1:200 ITS-X + 10 mg/mL Heparin + 100 nM LDN + 10 mM ALK5inhII + 1 mM GC1 + 100 nM GSiXX + 10 mM Zinc Sulfate.
. Stage 7 media (7 days, change every second day): MCDB131 + 2 mM Glutmax + 1.5 g/L NaHCO3 + 2% BSA fV + 20 mM final glucose + 1:200 ITS-X + 10 mg/mL Heparin + 10 mM ALK5inhII + 1 mM GC1 + 10 mM Trolox + 1 mM N-Acetylcysteine (A9165, Sigma-Aldrich)+75
mM Resveratrol (R5010, Sigma-Aldrich)+20 mM JNK inhibitor (SP600125, #1496, Tocris)+2 mM R428 (S2841, Selleckchem).
To improve reproducibility and standardize the differentiation, small molecule compounds were prepared in batches of stage-specific supplements, enabling rapid differentiation media preparation and consistency between experiments:
S3 supplement preparation, 2500X stock SANT1 (2.5 mM) 100 mL 200 mL RA (10 mM) 100 mL 200 mL LDN (1 mM) 100 mL 200 mL TPB (2.5 mM) 80 mL 160 mL DMSO 20 mL 40 mL TOTAL 400 mL 800 mL S4 supplement preparation, 2500X stock LDN (1 mM) 200 mL 400 mL SANT1 (2.5 mM) 100 mL 200 mL TPB (2.5 mM) 40 mL 80 mL RA (10 mM) 10 mL 20 mL DMSO 50 mL 100 mL TOTAL 400 mL 800 mL S5 supplement preparation, 1500X stock RA (10 mM) 5 mL 10 mL SANT1 (2.5 mM) 100 mL 200 mL LDN (1 mM) 100 mL 200 mL GC1 (10 mM) 100 mL 200 mL GSiXX (1 mM) 100 mL 200 mL ALK5inhII (50 mM) 200 mL 400 mL DMSO 61.6 mL 123.2 mL TOTAL 666.6 mL 1333.2 mL
S6 supplement preparation, 2000X stock
ALK5inhII (50 mM) 200 mL 400 mL LDN (1 mM) 100 mL 200 mL GC1 (10 mM 100 mL 200 mL GSiXX (1 mM) 100 mL 200 mL TOTAL 500 mL 1000 mL
Flow cytometry analysis
Cytometry for definitive endoderm marker CXCR4+ was performed as previously described (Saarimäki-Vire et al., 2017) . For intracellular antigen pancreatic marker cytometry of Stage 4 or Stage 7, cells were dissociated with TrypLE for 5-10 min at 37˚C and resuspended in 5% FBS-containing PBS. Cells were fixed and permeabilized using Cytofix/Cytoperm (554714, BD Biosciences) as recommended by manufacturer. Primary or conjugated antibodies were incubated with the cells overnight at 4˚C in Perm/Wash buffer (554714, BD Biosciences) containing 4% FBS. Cells were washed 2x with Perm/Wash buffer and analysed using FACSCalibur cytometer (BD Biosciences) and FlowJo software (Tree Star Inc.).
Quantitative RT-PCR
Total RNA was isolated using NucleoSpin Plus RNA kit (Macherey-Nagel). SimpliNano (General Electric) spectrophotometer was used to measure RNA quality and concentration. A total of 1.5 mg RNA was denatured at 65˚C for 1 min and reverse transcribed (RT) with 0.5 mL Moloney murine leukemia virus (MMLV) reverse transcriptase (M1701, Promega), 0.2 mL Random Primers (C1181, Promega), 1 mL Oligo(dT)18 Primer (SO131, ThermoFisher) and 0.5 mL Ribolock RNAse inhibitor (EO0382, ThermoFisher) for 90 min at 37˚C. qRT-PCR reactions were prepared with 50 ng of retrotranscribed RNA were amplified with 5 mL of forward and reverse primer mix at 2 mM each using 5x HOT FIREPol EvaGreen qPCR Mix Plus (no ROX) in a final volume of 20 mL. QIAgility (Quiagen) liquid handling system was used for pipetting the reactions into 100 well disc that were subsequently sealed and run in Rotor-Gene Q (Qiagen) with a thermal cycle of 95˚C for 15 min, followed by 40 cycles of 95˚C, 25 s; 57˚C, 25 s; 72˚C, 25 s, followed by a melting step. Relative quantification of gene expression was analysed using DDCt method, with cyclophilin G (PPIG) as endogenous housekeeping control gene. RT-reaction without template was used as negative control and exogenous positive control was used as a calibrator. (Klein et al., 2015) was implemented following the protocol as previously described (Zilionis et al., 2017) . Briefly, stage 7 islet-like aggregates were dissociated into single cells by incubation with a 1:1 mixture of TrypLE Express and Trypsin-EDTA for 10 min at 37˚C. Dissociated cells were passed through a 30 mm strainer to remove cell clumps. Single cells were co-encapsulated into 3-4 nL droplets together with barcoded hydrogel beads and a mixture of reversetranscription (RT) and lysis reagents. Within every single droplet, a cell was lysed and cDNA tagged with a barcode during reverse transcription. The droplet emulsion was broken and the bulk material was taken through the following steps: i) second strand synthesis; ii) linear amplification by in vitro transcription (IVT); amplified RNA fragmentation; iv) reverse transcription; v) PCR. In total, four samples from independent experiments were processed. They were produced in two parallel differentiation runs from HEL71.4 mutant and HEL71.4-A2 corrected iPSC lines, that were encapsulated at two different timepoints. The resulting DNA libraries were multiplexed and sequenced together on NextSeq Illumina platform in paired-end mode using a high-yield 75 cycle kit. Read quality was assessed by running FASTQC (version 0.10.1).
Sequencing read processing
To process the sequencing reads and to generate count matrices, a previously published set of Python scripts were used (Klein et al., 2015; Zilionis et al., 2017) (Supplementary materials). Briefly, raw transcript reads were trimmed with Trimmomatic 0.36, and barcode reads were filtered for expected structure (known cellular barcode, W1 sequence, poly-T tail). Modifications to the original scripts include a hamming distance of 5 for W1 sequence matching and minimum poly-T length of 3 for the barcode reads. Filtered reads were sorted based on barcodes, and barcodes having at least 20 000 reads were kept. The filtered reads were aligned with bowtie 1.1.1 (Langmead et al., 2009) to the Ensembl GRCh38 cDNA reference from which haplotypic transcripts were removed. A poly-A sequence of 125 bases was added to each transcript before building the bowtie index. Details on read alignment and UMI quantification arguments can be found in the supplementary materials. Percentages of unaligned reads per barcode were recorded from the script output and used in count matrix quality control. See also Supplementary file 1 - Table 9 .
Count matrix quality control
We examined the percentages of unmapped reads, total numbers of counts, detected genes per cell, and percentages of apoptotic and mitochondrial counts of cells, and removed the outliers based on these metrics. Cells with less than 50% unmapped reads were kept. Cells with total numbers of counts and detected genes three median-absolute-deviations above or below the median (log 10 scale) in a given sample were removed. Cells with over 2% apoptosis gene counts (3 out of 1295 mutant and 2 out of 992 corrected cells) were filtered out. As apoptosis genes, the HALLMAR-K_APOPTOSIS gene set from Broad Institute's Molecular Signatures Database (MSigDB) was used. The distributions of mitochondrial counts per cell were different between genotypes: the proportions were higher for corrected samples and the upper tail of their distribution extended further (Figure 2-figure supplement 3) . The thresholds for filtering cells were adjusted accordingly: 20% for mutant cells, and 40% for corrected cells (corresponding to values 3.5 standard deviations above the mean, 22 out of 1295 mutant cells and 17 out of 992 corrected cells were removed based on their mitochondrial gene expression) (Figure 2-source data 2) . The R package scater 1.4.0 was used for quality control of count data. See also Supplementary file 1 - Table 9 .
Clustering
Clustering was performed with Seurat 2.0.1 (Satija, R., Butler, A. and Hoffman, P., 2017 . Seurat: Tools for Single Cell Genomics. R package version 2.0.1. https://CRAN.R-project.org/package= Seurat). The samples were divided into genotype groups and normalized regressing out the sample identity and total number of counts (nUMI). The genotype groups were combined using Seurat's integration strategy in which datasets are aligned based on their shared gene correlation structure (Butler et al., 2018) . Canonical correlation analysis (CCA) was performed on the data sets to identify their common sources of variation. For CCA, the union of the 1000 most highly variable genes in the two data sets was used. The first 8 CCA dimensions were used to align the mutant and corrected samples with Seurat's AlignSubspaces function. The cells were clustered in aligned CCA space (eight dimensions) with Seurat's FindClusters function using a resolution of 0.8 and the SLM algorithm. Sample identity and nUMI were passed as latent variables to the clustering function. Clusters that had less than 20 differentially expressed (DE) genes with a fold change of 1.5 (FDR = 5%) between them were merged. DE genes for all pairs of clusters were identified with Seurat's function FindMarkers with the following arguments: min.pct = 0, test.use = 'negbinom', thresh.use = log(1.5), only.pos = F, latent.vars = c('sample','nUMI').
Cluster robustness was evaluated using a resampling procedure following Joost et al. (2016) (Joost et al., 2016) . Briefly, a thousand random subsamples (75% of the cells before cluster merging and refinement) were selected without replacement and clustered with arguments equivalent to the original run. For each original cluster, the maximum proportion of cells co-clustered in each subsample was recorded. The same procedure was repeated for shuffled cluster-cell pairs, to determine the null distribution of co-clustering proportions.
The cells were mapped to the adult human pancreas data of Baron et al. (2016) using the R package scmap 1.0.0 (Kiselev et al., 2018) . The Baron et al. (2016) data were downloaded from https://hemberg-lab.github.io/scRNA.seq.datasets/ and used to create an scmap reference. The reference was created using 250 genes selected with scmap's getFeatures function from the genes common to both data sets. For projecting cells onto the reference, a similarity threshold of 0.6 was used. Cells in the beta-like and progenitor clusters mapping to alpha cells were moved to the alphalike cluster. Cells mapping to delta and ductal cells (25 and 1 cells, respectively) were removed from the data set.
Cluster markers were identified using Seurat's function FindAllMarkers with the following arguments: thresh.use = log(1.5), test.use = 'negbinom', min.pct = 0, latent.vars = ('sample','nUMI'), only.pos = T, return.thresh = 1. The p-values of the tests were adjusted for multiple testing with the Benjamini-Hochberg method.
Dimensionality reduction with t-SNE was performed using Seurat's RunTSNE function with the following arguments: reduction.use = 'cca.aligned', dims.use = 1:8, do.fast = T, perplexity = 70.
Differential expression between mutant and corrected cells
For cells in the refined beta-like and progenitor clusters, differential expression between mutant and corrected cells was tested with MAST 1.4.0 (Finak et al., 2015) . The expression data used were lognormalized values (Seurat default) with base changed to 2. Only genes expressed in at least 3 cells in both genotype groups were considered. A hurdle model was fitted with terms for genotype and encapsulation day, and the genotype effect was tested with a likelihood ratio test. P-values were adjusted for multiple testing using the Benjamini-Hochberg method. Genes with fold changes of at least 1.3 and adjusted p-values below 0.05 were considered differentially expressed.
Functional enrichment analysis
The statistical overrepresentation test for GO terms was performed with PANTHER at www.pantherdb.org. The binomial test was run with default settings using lists of gene names, the biological process (BP) category, and all human genes in the database as reference. Bonferroni correction for multiple testing was used. GSEA was performed with CAMERA of the R package limma 3.32.6. The curated C2 gene sets were downloaded from MSigDB. The same gene expression values and linear model formula were used for GSEA and differential expression tests with MAST. Only genes expressed in at least 3 cells in both genotype groups were considered. An FDR of 5% was used as the threshold for statistical significance.
Pseudotime analysis
Pseudotime analysis was performed with the R package Monocle 2.4.0 (Qiu et al., 2017) . The mutant and corrected samples were processed and ordered together. Highly variable genes used for ordering (with empirical dispersion at least two times greater than the dispersion fit) were selected from the corrected samples only, to avoid biasing the ordering by the mutant cells. Dimensionality of the data was reduced with the DDRTree algorithm.
Sample identity was used in the residual model formula to reduce sample-specific effects on ordering. This was done to enable side-by-side comparison of mutant and corrected cells on the same trajectory. Branch dependent genes, for examining the differences between progenitor branches, were identified with Monocle 2's BEAM function controlling for sample identity. Pseudotime was reversed by applying max P ð Þ À p, where P is the set of pseudotime values, to each pseudotime value p. Pseudotime-dependent genes were identified with Monocle 2's differentialGeneTest function. The test was performed separately for mutant and corrected samples controlling for sample identity. The union of pseudotime-dependent genes (q-value < 0.05%) of the mutant and corrected samples were further used for testing e differentially expressed genes between genotypes along pseudotime. This test was performed with Monocle 2's function differentialGeneTest using the combined data, controlling for encapsulation date and pseudotime. A q-value of 0.05 was set as the threshold of statistical significance. Scripts used for these analyses can be found in the Supplementary materials.
Induction of apoptosis by ER-stress inducers
One hundred manually picked Stage 7 islet-like aggregates were incubated in full Stage 7 media with the corresponding concentration ER-stress inducers. Brefeldin A (B5936, Sigma-Aldrich) was used at 1 mg/mL in DMSO for 24 hr. Thapsigargin (T9033, Sigma-Aldrich) and tunicamycin (T7765, Sigma-Aldrich) were used at 1 mM and 5 mg/mL respectively for 48 hr. DMSO was used as a vehicle control at 5 mL/mL. Aggregates were collected and PFA-fixed for immunohistochemistry after treatment.
Static glucose stimulated insulin secretion
Stage 7 islet-like aggregates were sampled in groups of 100 to 1.5 mL tubes. They were washed twice with Krebs buffer containing no glucose and then transferred to 12-well plate placed in a rotating platform for incubation in 3.3 mM glucose-containing Krebs buffer for 1 hr (low glucose). This was performed twice. Then aggregates were incubated sequentially in 3.3 mM glucose, 20 mM glucose, 20 mM glucose + 100 mM tolbutamide and 3.3 mM + 30 mM KCl, for a period of 30 min, with two washes with 1 mL Krebs buffer containing no glucose between treatments. 500 mL of supernatant from each treatment incubation were collected, centrifuged to remove possible cells in suspension and stored at À80˚C for ELISA-based determination of human insulin concentration. After the last treatment incubation, samples were retrieved and lysed in acid ethanol for determination of total insulin content and DNA content. Stimulated insulin secretion results are presented as fractional release of total human insulin content after cell mass normalization using total DNA content.
Transplantation of differentiated cells
NOD-SCID-gamma (NSG) (Jackson Laboratories; 005557) mice were housed at Biomedicum Helsinki animal facility, on a 12 hr light/dark cycle and food ad libitum. Transplantations were performed on 3-to 12-month-old mice as described previously (Saarimäki-Vire et al., 2017) . Briefly, aggregates equivalent to approximately 5 million cells were loaded on a PE-50 tubing and transplanted under the kidney capsule. Mice were anesthetized with isoflurane. Carprofen (Rimadyl, 5 mg/kg, subcutaneously, Prizer, Helsinki, Finland) and Buprenorphine (Temgesic, 0,05-0,1 mg/kg, subcutaneously, RB pharmaceuticals Lmt, Berkshire, UK) were used as analgesics during the operation and in the following day. Mouse blood samples were collected monthly from the saphenous vein using heparinized capillary tubes. Blood plasma was separated by centrifugation (5000 rcf, 5 min, RT).
Intraperitoneal glucose tolerance test (IPGTT)
IPGTT was performed after 6-8 hr fast. 2 g glucose/kg of body weight was injected intraperitoneally in the form of a 30% glucose solution in water. Blood glucose levels were measured with glucometer (OneTouch Ultra, Lifescan, Milpitas; USA) at 0, 20, 40 and 60 min after glucose injection. Blood samples for measuring human c-peptide levels were taken before, and 40 min after glucose injection.
ELISA
Human c-peptide and proinsulin levels were measured from plasma samples and cell supernatants with Ultrasensitive C-PEPTIDE ELISA (Mercodia, Sweden) and PRO-INSULIN (Mercodia, Sweden) according to manufacturer's instructions. Human MANF levels were measured using in-lab ELISA (Galli et al. 2016 ).
Immunocytochemistry and histology
Cells on adherent cultures were fixed in 4% PFA for 15-20 min, permeabilized with 0.5% triton-X100 in 1x PBS, blocked with UltraV block (ThermoFisher) for 10 min and incubated with primary antibodies diluted in 0.1% Tween in 1 x PBS at 4˚C overnight. Cells were washed with 1 x PBS, incubated with secondary antibodies diluted in 0.1% Tween in PBS. Same procedure was used for whole-mount staining of Stage 7 cell aggregates. For paraffin embedding, Stage 7 cell aggregates were fixed with 4% PFA at RT overnight and briefly stained with Eosin. After this, they were embedded in low-melting Agarose (Sigma-Aldrich) and transferred to paraffin blocks. Grafts were retrieved after IPGTT, dissected and fixed with 4% PFA in RT overnight and placed into cassettes and processed for tissue transfer and paraffin embedding. Paraffin blocks were cut into 5 mm sections. For immunohistochemistry, slides were deparaffinised and antigen retrieval was performed by boiling slides either in 1 mM EDTA or 0.1 M citrate buffer. Blocking and incubation with primary and secondary antibodies were done as described for fixed cells above. For TUNEL analysis, paraffin sections were processed with In Situ Cell death Detection Fluorescein kit (Roche, #11684795910) according to manufacturer's instructions. See Key Resource 
Image acquisition and analysis
Immunofluorescence stainings of adherent cells were imaged with EVOS inverted microscope (LifeTechnologies). Paraffin sections and whole-mount stainings were imaged with Zeiss Axio Observer Z1 with Apotome two and processed with ZEN2 software blue edition. To ensure reliable quantification of the immunostainings, all paraffin sections were stained simultaneously and imaged on the same session with the same microscope parameters. Image quantifications were performed blindly using Fiji software (Schindelin et al., 2012) . Quantification of individual cell immunostaining intensity was performed manually using Fiji ROI Manager and Multi Measure tools. Fiji pixel intensity and Cell counter tools were used to score percentages of cells positive, negative, low or high across the different immunostainings.
Statistical analyses
Statistical analyses were performed with GraphPad Prism (version 7.0 c, GraphPad Software). Data were tested for normal distribution using Shapiro-Wilk normality test. Normally distributed data were analyzed to compare the means of two samples using unpaired two-tailed Student's t test, with Welch's correction in the case of samples with unequal variance as determined by F test. Oneway ANOVA with multiple comparison Tukey test was used to compare the means of more than two samples. When the data groups were not normally distributed or the sample size was too small, the non-parametric Mann-Whitney U test and Kruskal-Wallis test with the Dunn multiple comparisons test were used to compare the sum of ranks. Details on the statistical analyses performed are described in the figure legends. Data are presented as individual value points and/or the mean as summary statistic with error bars representing the Standard Error of the Mean (SEM). P-values under 0.05 were considered statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001).
Study approval
The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (no. 423/13/03/00/ 08) approved the patient informed consent for the derivation of the hiPSC lines used in this study: HEL71.4 and HEL107.2.
Animal care and experiments were approved by National Animal Experiment Board in Finland (ESAVI/9978/04.10.07/2014).
